DHX33: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: DHX33

NCBI ID: G56919

DHX33

DHX33: A Potential Drug Target Or Biomarker for Various Diseases

DHX33 (DHX33_HUMAN) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique feature is its high homology with the human heat shock protein (HSP70), which is known for its ability to interact with various drugs and molecules to enhance their therapeutic effects.

The discovery of DHX33 was made using a technique called transcriptomics, which involves the analysis of gene expression in a sample. Researchers found that DHX33 was expressed in various tissues and cells of the human body, including the brain, heart, liver, and pancreas. Additionally, they found that DHX33 was highly expressed in cancer tissues, which suggests that it may be a promising biomarker for cancer.

One of the reasons DHX33 is considered a potential drug target is its role in the regulation of cellular stress responses. DHX33 is a part of the HSP70 family, which is well-known for its ability to regulate cellular stress responses. In fact, DHX33 is highly expressed in tissues that are often exposed to stress, such as the lungs and the kidneys. This suggests that it may play a role in stress responses related to various diseases, including cancer.

Another potential drug target for DHX33 is its role in the regulation of inflammation. DHX33 has been shown to be involved in the regulation of inflammatory responses, which may make it a promising target for interventions aimed at reducing inflammation. Additionally, DHX33 has been shown to interact with various cytokines, which are involved in inflammation. This suggests that it may play a role in modulating the inflammatory response.

DHX33 may also be a potential biomarker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, which can lead to a range of symptoms, including cognitive decline and motor dysfunction. DHX33 has been shown to be involved in the regulation of neurodegenerative diseases, which suggests that it may be a promising biomarker for these conditions.

In conclusion, DHX33 is a gene that has been identified as a potential drug target or biomarker for various diseases. Its unique feature is its high homology with the human HSP70, which may make it a promising target for interventions aimed at reducing cellular stress responses, inflammation, and neurodegenerative diseases. Further research is needed to fully understand the role of DHX33 in these conditions and to develop safe and effective therapies.

Protein Name: DEAH-box Helicase 33

Functions: Implicated in nucleolar organization, ribosome biogenesis, protein synthesis and cytoplasmic dsRNA sensing (By similarity) (PubMed:21930779, PubMed:23871209, PubMed:26100019). Stimulates RNA polymerase I transcription of the 47S precursor rRNA. Associates with ribosomal DNA (rDNA) loci where it is involved in POLR1A recruitment (PubMed:21930779). In the cytoplasm, promotes elongation-competent 80S ribosome assembly at the late stage of mRNA translation initiation (PubMed:26100019). Senses cytosolic dsRNA mediating NLRP3 inflammasome formation in macrophages and type I interferon production in myeloid dendritic cells (PubMed:23871209). Required for NLRP3 activation induced by viral dsRNA and bacterial RNA (PubMed:23871209). In dendritic cells, required for induction of type I interferon production induced by cytoplasmic dsRNA via the activation of MAPK and NF-kappa-B signaling pathways (By similarity)

The "DHX33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHX33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets